| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Stroke | 19 | 2017 | 1087 | 1.310 |
Why?
|
| Brain Ischemia | 12 | 2017 | 416 | 1.290 |
Why?
|
| Angioplasty | 8 | 2014 | 71 | 0.760 |
Why?
|
| Carotid Stenosis | 5 | 2012 | 115 | 0.750 |
Why?
|
| Stents | 10 | 2012 | 425 | 0.730 |
Why?
|
| Ischemic Attack, Transient | 4 | 2017 | 188 | 0.700 |
Why?
|
| Ovarian Neoplasms | 3 | 2016 | 828 | 0.600 |
Why?
|
| Embolization, Therapeutic | 5 | 2016 | 279 | 0.520 |
Why?
|
| Delayed Diagnosis | 1 | 2017 | 41 | 0.520 |
Why?
|
| Vitamin D3 24-Hydroxylase | 1 | 2016 | 6 | 0.500 |
Why?
|
| Progesterone | 1 | 2016 | 112 | 0.490 |
Why?
|
| Chemoprevention | 1 | 2016 | 93 | 0.490 |
Why?
|
| Thrombolytic Therapy | 8 | 2012 | 261 | 0.480 |
Why?
|
| Vertebral Artery Dissection | 3 | 2012 | 20 | 0.480 |
Why?
|
| Calcitriol | 1 | 2016 | 173 | 0.470 |
Why?
|
| Tissue Plasminogen Activator | 6 | 2012 | 181 | 0.420 |
Why?
|
| Endovascular Procedures | 7 | 2016 | 334 | 0.410 |
Why?
|
| Angioplasty, Balloon | 3 | 2012 | 100 | 0.400 |
Why?
|
| Carotid Artery, Internal | 3 | 2009 | 70 | 0.380 |
Why?
|
| Intracranial Aneurysm | 4 | 2016 | 206 | 0.350 |
Why?
|
| Fibrinolytic Agents | 8 | 2012 | 240 | 0.330 |
Why?
|
| Allosteric Regulation | 1 | 2010 | 70 | 0.320 |
Why?
|
| Psychotropic Drugs | 1 | 2010 | 82 | 0.300 |
Why?
|
| Hypovolemia | 1 | 2008 | 3 | 0.300 |
Why?
|
| Dehydration | 1 | 2008 | 20 | 0.300 |
Why?
|
| Drinking | 1 | 2008 | 35 | 0.300 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2010 | 164 | 0.290 |
Why?
|
| Evolution, Molecular | 2 | 2016 | 891 | 0.280 |
Why?
|
| Minnesota | 7 | 2017 | 50 | 0.270 |
Why?
|
| Vasospasm, Intracranial | 3 | 2014 | 36 | 0.270 |
Why?
|
| Humans | 55 | 2017 | 96127 | 0.260 |
Why?
|
| Models, Molecular | 2 | 2016 | 1375 | 0.260 |
Why?
|
| Moyamoya Disease | 1 | 2007 | 21 | 0.250 |
Why?
|
| Female | 39 | 2017 | 50063 | 0.250 |
Why?
|
| Risk Factors | 16 | 2015 | 5960 | 0.250 |
Why?
|
| Subarachnoid Hemorrhage | 3 | 2014 | 154 | 0.250 |
Why?
|
| Endarterectomy, Carotid | 3 | 2012 | 76 | 0.240 |
Why?
|
| Leukemia, Radiation-Induced | 1 | 2015 | 14 | 0.240 |
Why?
|
| Aged | 29 | 2015 | 20964 | 0.240 |
Why?
|
| Middle Aged | 32 | 2017 | 28363 | 0.230 |
Why?
|
| Time-to-Treatment | 3 | 2017 | 140 | 0.230 |
Why?
|
| Seizures | 1 | 2008 | 331 | 0.220 |
Why?
|
| Emergency Medical Services | 3 | 2013 | 271 | 0.220 |
Why?
|
| Aged, 80 and over | 16 | 2015 | 7232 | 0.220 |
Why?
|
| Patient Admission | 2 | 2017 | 122 | 0.220 |
Why?
|
| Diagnostic Imaging | 1 | 2008 | 475 | 0.210 |
Why?
|
| Time Factors | 12 | 2017 | 5585 | 0.210 |
Why?
|
| Estrogen Replacement Therapy | 1 | 2013 | 48 | 0.200 |
Why?
|
| Male | 35 | 2017 | 45870 | 0.200 |
Why?
|
| Retrospective Studies | 17 | 2017 | 10286 | 0.200 |
Why?
|
| Emergency Service, Hospital | 4 | 2014 | 594 | 0.200 |
Why?
|
| Genetic Predisposition to Disease | 3 | 2015 | 2473 | 0.190 |
Why?
|
| Treatment Outcome | 18 | 2016 | 9173 | 0.180 |
Why?
|
| Breast | 1 | 2013 | 297 | 0.180 |
Why?
|
| Chi-Square Distribution | 6 | 2014 | 363 | 0.170 |
Why?
|
| Vasodilator Agents | 2 | 2014 | 151 | 0.170 |
Why?
|
| Patient Selection | 5 | 2012 | 709 | 0.170 |
Why?
|
| Cerebral Angiography | 3 | 2012 | 217 | 0.170 |
Why?
|
| Adult | 20 | 2017 | 28718 | 0.170 |
Why?
|
| Carotid Artery Diseases | 2 | 2011 | 103 | 0.170 |
Why?
|
| Genes, BRCA2 | 3 | 2015 | 162 | 0.170 |
Why?
|
| Genes, BRCA1 | 3 | 2015 | 192 | 0.160 |
Why?
|
| Intracranial Hemorrhages | 2 | 2012 | 136 | 0.160 |
Why?
|
| Body Mass Index | 1 | 2013 | 815 | 0.160 |
Why?
|
| Signal Transduction | 1 | 2010 | 3586 | 0.150 |
Why?
|
| Aneurysm, Ruptured | 2 | 2016 | 62 | 0.140 |
Why?
|
| Tomography, X-Ray Computed | 7 | 2014 | 2781 | 0.140 |
Why?
|
| Risk Assessment | 6 | 2015 | 2480 | 0.140 |
Why?
|
| Breast Neoplasms | 3 | 2015 | 3147 | 0.140 |
Why?
|
| Morphine Derivatives | 1 | 2017 | 8 | 0.140 |
Why?
|
| Botulism | 1 | 2017 | 6 | 0.140 |
Why?
|
| Heroin Dependence | 1 | 2017 | 16 | 0.140 |
Why?
|
| Wound Infection | 1 | 2017 | 18 | 0.140 |
Why?
|
| Injections, Subcutaneous | 1 | 2017 | 134 | 0.130 |
Why?
|
| Phosphoinositide Phospholipase C | 1 | 2017 | 6 | 0.130 |
Why?
|
| Abscess | 1 | 2017 | 95 | 0.130 |
Why?
|
| Inositol 1,4,5-Trisphosphate Receptors | 1 | 2017 | 17 | 0.130 |
Why?
|
| United States | 11 | 2014 | 7767 | 0.130 |
Why?
|
| Receptors, Adrenergic, beta-2 | 1 | 2017 | 39 | 0.130 |
Why?
|
| Epinephrine | 1 | 2017 | 92 | 0.130 |
Why?
|
| Predictive Value of Tests | 3 | 2017 | 1807 | 0.130 |
Why?
|
| Norepinephrine | 1 | 2017 | 174 | 0.130 |
Why?
|
| Registries | 5 | 2015 | 986 | 0.120 |
Why?
|
| Calcium Signaling | 1 | 2017 | 142 | 0.120 |
Why?
|
| Sturge-Weber Syndrome | 1 | 2016 | 9 | 0.120 |
Why?
|
| Drug Synergism | 1 | 2016 | 318 | 0.120 |
Why?
|
| Receptors, Dopamine D2 | 1 | 2016 | 57 | 0.120 |
Why?
|
| Arteriovenous Fistula | 1 | 2016 | 54 | 0.120 |
Why?
|
| Endoplasmic Reticulum | 1 | 2017 | 264 | 0.120 |
Why?
|
| Receptors, Progesterone | 1 | 2016 | 195 | 0.120 |
Why?
|
| Ovary | 1 | 2016 | 268 | 0.110 |
Why?
|
| Logistic Models | 5 | 2014 | 1268 | 0.110 |
Why?
|
| Neoplasms, Unknown Primary | 1 | 2014 | 13 | 0.110 |
Why?
|
| Radiography | 3 | 2012 | 826 | 0.110 |
Why?
|
| Infusions, Intravenous | 2 | 2012 | 423 | 0.110 |
Why?
|
| Brain Infarction | 2 | 2013 | 24 | 0.110 |
Why?
|
| Antineoplastic Agents | 1 | 2015 | 2422 | 0.110 |
Why?
|
| Age Factors | 5 | 2015 | 1963 | 0.110 |
Why?
|
| Odds Ratio | 4 | 2014 | 713 | 0.110 |
Why?
|
| Fallopian Tube Neoplasms | 1 | 2014 | 39 | 0.110 |
Why?
|
| Cell Survival | 1 | 2016 | 1032 | 0.100 |
Why?
|
| Emergency Medical Technicians | 1 | 2013 | 14 | 0.100 |
Why?
|
| Remote Consultation | 1 | 2013 | 16 | 0.100 |
Why?
|
| Binding Sites | 3 | 2016 | 1167 | 0.100 |
Why?
|
| Cerebral Arterial Diseases | 1 | 2013 | 7 | 0.100 |
Why?
|
| Hyperbaric Oxygenation | 1 | 2013 | 13 | 0.100 |
Why?
|
| Embolism, Air | 1 | 2013 | 24 | 0.100 |
Why?
|
| Advance Directives | 1 | 2013 | 64 | 0.100 |
Why?
|
| Diagnosis, Differential | 1 | 2017 | 1619 | 0.100 |
Why?
|
| Hospital Mortality | 2 | 2012 | 483 | 0.090 |
Why?
|
| Lynch Syndrome II | 1 | 2012 | 1 | 0.090 |
Why?
|
| Cerebral Infarction | 1 | 2012 | 74 | 0.090 |
Why?
|
| Talc | 1 | 2012 | 4 | 0.090 |
Why?
|
| Pelvic Inflammatory Disease | 1 | 2012 | 9 | 0.090 |
Why?
|
| Hemostatic Techniques | 1 | 2012 | 19 | 0.090 |
Why?
|
| Progestins | 1 | 2012 | 23 | 0.090 |
Why?
|
| Gonadotropins | 1 | 2012 | 34 | 0.090 |
Why?
|
| Contraceptives, Oral, Hormonal | 1 | 2012 | 18 | 0.090 |
Why?
|
| Endometrial Neoplasms | 1 | 2015 | 228 | 0.090 |
Why?
|
| Sterilization, Tubal | 1 | 2012 | 12 | 0.090 |
Why?
|
| General Practice | 1 | 2011 | 9 | 0.090 |
Why?
|
| Parity | 1 | 2012 | 97 | 0.090 |
Why?
|
| Intracranial Arterial Diseases | 1 | 2011 | 3 | 0.090 |
Why?
|
| Femoral Artery | 1 | 2012 | 91 | 0.090 |
Why?
|
| Carotid Artery, Internal, Dissection | 1 | 2011 | 31 | 0.090 |
Why?
|
| Endometriosis | 1 | 2012 | 63 | 0.090 |
Why?
|
| Catheterization, Peripheral | 1 | 2012 | 64 | 0.090 |
Why?
|
| Constriction, Pathologic | 1 | 2012 | 220 | 0.090 |
Why?
|
| Myocardial Infarction | 1 | 2015 | 429 | 0.090 |
Why?
|
| Stroke Rehabilitation | 1 | 2012 | 50 | 0.090 |
Why?
|
| Androgens | 1 | 2012 | 179 | 0.090 |
Why?
|
| Nervous System Diseases | 1 | 2012 | 172 | 0.090 |
Why?
|
| Geography | 1 | 2012 | 240 | 0.090 |
Why?
|
| Cerebrovascular Disorders | 1 | 2012 | 146 | 0.090 |
Why?
|
| Aneurysm, False | 1 | 2011 | 55 | 0.090 |
Why?
|
| Estrogens | 1 | 2012 | 203 | 0.090 |
Why?
|
| Hormone Replacement Therapy | 1 | 2012 | 97 | 0.090 |
Why?
|
| Self Care | 1 | 2012 | 170 | 0.090 |
Why?
|
| Epithelium | 1 | 2012 | 326 | 0.090 |
Why?
|
| Recurrence | 3 | 2014 | 1218 | 0.080 |
Why?
|
| Trauma Centers | 1 | 2012 | 174 | 0.080 |
Why?
|
| Life Style | 1 | 2012 | 186 | 0.080 |
Why?
|
| Breast Feeding | 1 | 2012 | 108 | 0.080 |
Why?
|
| Ticlopidine | 1 | 2010 | 26 | 0.080 |
Why?
|
| Thrombectomy | 1 | 2012 | 220 | 0.080 |
Why?
|
| Hysterectomy | 1 | 2012 | 168 | 0.080 |
Why?
|
| International Classification of Diseases | 1 | 2010 | 67 | 0.080 |
Why?
|
| Guideline Adherence | 1 | 2012 | 245 | 0.080 |
Why?
|
| Cell Line, Tumor | 1 | 2016 | 2794 | 0.080 |
Why?
|
| Clinical Trials as Topic | 2 | 2012 | 1178 | 0.080 |
Why?
|
| Hemorrhage | 1 | 2012 | 294 | 0.080 |
Why?
|
| Medical Oncology | 1 | 2014 | 408 | 0.080 |
Why?
|
| Fluorescence | 1 | 2010 | 106 | 0.080 |
Why?
|
| Mutagenesis | 1 | 2010 | 202 | 0.080 |
Why?
|
| Ultrasonography, Doppler, Transcranial | 1 | 2009 | 18 | 0.080 |
Why?
|
| Patient Transfer | 1 | 2010 | 108 | 0.080 |
Why?
|
| Nicardipine | 1 | 2009 | 7 | 0.080 |
Why?
|
| Aspirin | 1 | 2010 | 169 | 0.080 |
Why?
|
| Magnesium Sulfate | 1 | 2009 | 16 | 0.080 |
Why?
|
| Protein Conformation | 2 | 2010 | 935 | 0.080 |
Why?
|
| Biomedical Research | 1 | 2014 | 441 | 0.080 |
Why?
|
| Thirst | 1 | 2008 | 19 | 0.070 |
Why?
|
| Terminology as Topic | 1 | 2010 | 229 | 0.070 |
Why?
|
| Mice, Inbred C57BL | 1 | 2016 | 3490 | 0.070 |
Why?
|
| Patient Discharge | 1 | 2012 | 361 | 0.070 |
Why?
|
| Diet | 1 | 2012 | 461 | 0.070 |
Why?
|
| Osmolar Concentration | 1 | 2008 | 180 | 0.070 |
Why?
|
| Blood Vessel Prosthesis | 1 | 2010 | 248 | 0.070 |
Why?
|
| Exercise | 1 | 2012 | 354 | 0.070 |
Why?
|
| Diuretics | 1 | 2008 | 79 | 0.070 |
Why?
|
| Incidence | 4 | 2015 | 1715 | 0.070 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2010 | 209 | 0.070 |
Why?
|
| Case-Control Studies | 2 | 2012 | 1958 | 0.070 |
Why?
|
| Ophthalmoplegia | 1 | 2008 | 12 | 0.070 |
Why?
|
| Length of Stay | 2 | 2011 | 833 | 0.070 |
Why?
|
| Analgesics | 1 | 2009 | 132 | 0.070 |
Why?
|
| Smoking | 1 | 2012 | 653 | 0.070 |
Why?
|
| Decision Making | 1 | 2013 | 694 | 0.070 |
Why?
|
| Intracranial Embolism | 1 | 2008 | 30 | 0.070 |
Why?
|
| Craniocerebral Trauma | 1 | 2008 | 60 | 0.070 |
Why?
|
| Survival Rate | 4 | 2012 | 1986 | 0.070 |
Why?
|
| Emergencies | 1 | 2008 | 124 | 0.070 |
Why?
|
| Recombinant Proteins | 3 | 2016 | 1034 | 0.060 |
Why?
|
| Microsurgery | 1 | 2007 | 99 | 0.060 |
Why?
|
| Feasibility Studies | 3 | 2014 | 819 | 0.060 |
Why?
|
| Inflammation | 1 | 2012 | 1068 | 0.060 |
Why?
|
| Physicians | 1 | 2013 | 707 | 0.060 |
Why?
|
| Cell Line | 1 | 2010 | 2533 | 0.060 |
Why?
|
| Adolescent | 3 | 2016 | 9896 | 0.060 |
Why?
|
| Practice Guidelines as Topic | 1 | 2012 | 1096 | 0.060 |
Why?
|
| Obesity | 1 | 2012 | 1034 | 0.060 |
Why?
|
| Survivors | 1 | 2015 | 204 | 0.050 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 1 | 2007 | 301 | 0.050 |
Why?
|
| Pregnancy | 1 | 2012 | 3240 | 0.050 |
Why?
|
| Cerebral Hemorrhage | 1 | 2008 | 374 | 0.050 |
Why?
|
| HEK293 Cells | 2 | 2017 | 706 | 0.050 |
Why?
|
| Mutation | 2 | 2014 | 4374 | 0.050 |
Why?
|
| Prevalence | 3 | 2012 | 1349 | 0.050 |
Why?
|
| Antidepressive Agents | 1 | 2003 | 113 | 0.050 |
Why?
|
| Postmenopause | 1 | 2013 | 107 | 0.050 |
Why?
|
| Transportation of Patients | 2 | 2013 | 35 | 0.050 |
Why?
|
| Prognosis | 2 | 2015 | 4033 | 0.050 |
Why?
|
| Germ-Line Mutation | 1 | 2015 | 381 | 0.050 |
Why?
|
| Neoplasms | 2 | 2015 | 3250 | 0.050 |
Why?
|
| Membrane Transport Proteins | 1 | 2003 | 170 | 0.050 |
Why?
|
| Body Weight | 1 | 2013 | 460 | 0.050 |
Why?
|
| Mice | 1 | 2016 | 12562 | 0.050 |
Why?
|
| Cerebral Arteries | 2 | 2014 | 76 | 0.050 |
Why?
|
| Angiography, Digital Subtraction | 2 | 2012 | 100 | 0.040 |
Why?
|
| Equipment Design | 2 | 2013 | 427 | 0.040 |
Why?
|
| Membrane Glycoproteins | 1 | 2003 | 453 | 0.040 |
Why?
|
| Disease-Free Survival | 2 | 2015 | 1195 | 0.040 |
Why?
|
| Nerve Tissue Proteins | 1 | 2003 | 515 | 0.040 |
Why?
|
| Acute Disease | 2 | 2013 | 872 | 0.040 |
Why?
|
| Carrier Proteins | 1 | 2003 | 684 | 0.040 |
Why?
|
| Mammography | 1 | 2013 | 475 | 0.040 |
Why?
|
| Recombinant Fusion Proteins | 2 | 2017 | 564 | 0.040 |
Why?
|
| Multivariate Analysis | 2 | 2013 | 1010 | 0.040 |
Why?
|
| Longitudinal Studies | 1 | 2013 | 1175 | 0.040 |
Why?
|
| Early Detection of Cancer | 1 | 2013 | 484 | 0.040 |
Why?
|
| Sex Factors | 2 | 2012 | 1133 | 0.040 |
Why?
|
| Animals | 2 | 2016 | 28945 | 0.030 |
Why?
|
| Comorbidity | 2 | 2012 | 1011 | 0.030 |
Why?
|
| Estrenes | 1 | 2017 | 8 | 0.030 |
Why?
|
| Pyrrolidinones | 1 | 2017 | 16 | 0.030 |
Why?
|
| Boron Compounds | 1 | 2017 | 20 | 0.030 |
Why?
|
| Thapsigargin | 1 | 2017 | 55 | 0.030 |
Why?
|
| Isoproterenol | 1 | 2017 | 62 | 0.030 |
Why?
|
| Sarcoplasmic Reticulum Calcium-Transporting ATPases | 1 | 2017 | 30 | 0.030 |
Why?
|
| Adrenergic beta-Agonists | 1 | 2017 | 75 | 0.030 |
Why?
|
| Follow-Up Studies | 2 | 2016 | 3927 | 0.030 |
Why?
|
| Calcium Channel Blockers | 1 | 2017 | 122 | 0.030 |
Why?
|
| CRISPR-Cas Systems | 1 | 2017 | 98 | 0.030 |
Why?
|
| Postoperative Complications | 1 | 2008 | 2591 | 0.030 |
Why?
|
| Protein Interaction Domains and Motifs | 1 | 2016 | 91 | 0.030 |
Why?
|
| Enzyme Activation | 1 | 2017 | 692 | 0.030 |
Why?
|
| GTP-Binding Proteins | 1 | 2016 | 148 | 0.030 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 2016 | 282 | 0.030 |
Why?
|
| Amino Acids | 1 | 2016 | 262 | 0.030 |
Why?
|
| Amino Acid Substitution | 1 | 2016 | 336 | 0.030 |
Why?
|
| Thermodynamics | 1 | 2016 | 329 | 0.030 |
Why?
|
| Serotonin | 1 | 2016 | 219 | 0.030 |
Why?
|
| CA-125 Antigen | 1 | 2014 | 22 | 0.030 |
Why?
|
| Severity of Illness Index | 2 | 2012 | 1981 | 0.030 |
Why?
|
| Ligands | 1 | 2016 | 478 | 0.030 |
Why?
|
| Injections, Intra-Arterial | 1 | 2014 | 34 | 0.030 |
Why?
|
| Kinetics | 1 | 2017 | 1562 | 0.030 |
Why?
|
| Dopamine | 1 | 2016 | 282 | 0.030 |
Why?
|
| Ovariectomy | 1 | 2014 | 91 | 0.030 |
Why?
|
| Foundations | 1 | 2014 | 15 | 0.030 |
Why?
|
| Public-Private Sector Partnerships | 1 | 2014 | 7 | 0.030 |
Why?
|
| Cerebral Revascularization | 1 | 2014 | 27 | 0.030 |
Why?
|
| International Agencies | 1 | 2014 | 34 | 0.030 |
Why?
|
| Government Agencies | 1 | 2014 | 13 | 0.030 |
Why?
|
| Thromboembolism | 1 | 2015 | 128 | 0.030 |
Why?
|
| Enzyme Inhibitors | 1 | 2017 | 657 | 0.030 |
Why?
|
| Africa | 1 | 2014 | 107 | 0.030 |
Why?
|
| National Cancer Institute (U.S.) | 1 | 2014 | 72 | 0.030 |
Why?
|
| Critical Pathways | 1 | 2014 | 36 | 0.030 |
Why?
|
| Emergency Medical Service Communication Systems | 1 | 2013 | 6 | 0.030 |
Why?
|
| Population Surveillance | 1 | 2015 | 218 | 0.030 |
Why?
|
| Community Participation | 1 | 2014 | 41 | 0.030 |
Why?
|
| Coronary Disease | 1 | 2015 | 263 | 0.030 |
Why?
|
| International Cooperation | 1 | 2014 | 134 | 0.030 |
Why?
|
| Ethics, Research | 1 | 2014 | 53 | 0.030 |
Why?
|
| Research Support as Topic | 1 | 2014 | 92 | 0.030 |
Why?
|
| Neoplasm Grading | 1 | 2015 | 404 | 0.030 |
Why?
|
| Silicones | 1 | 2013 | 21 | 0.020 |
Why?
|
| Disability Evaluation | 1 | 2014 | 171 | 0.020 |
Why?
|
| Prospective Studies | 2 | 2012 | 4671 | 0.020 |
Why?
|
| Universities | 1 | 2014 | 154 | 0.020 |
Why?
|
| Iatrogenic Disease | 1 | 2013 | 72 | 0.020 |
Why?
|
| Placebo Effect | 1 | 2012 | 35 | 0.020 |
Why?
|
| Clinical Protocols | 1 | 2013 | 162 | 0.020 |
Why?
|
| Brain Edema | 1 | 2013 | 61 | 0.020 |
Why?
|
| Neoplasm Invasiveness | 1 | 2014 | 590 | 0.020 |
Why?
|
| Triage | 1 | 2013 | 132 | 0.020 |
Why?
|
| Withholding Treatment | 1 | 2013 | 121 | 0.020 |
Why?
|
| Punctures | 1 | 2012 | 29 | 0.020 |
Why?
|
| Treatment Failure | 1 | 2013 | 297 | 0.020 |
Why?
|
| Interinstitutional Relations | 1 | 2012 | 30 | 0.020 |
Why?
|
| Catheterization | 1 | 2013 | 238 | 0.020 |
Why?
|
| Fibromuscular Dysplasia | 1 | 2011 | 11 | 0.020 |
Why?
|
| Databases as Topic | 1 | 2011 | 96 | 0.020 |
Why?
|
| Observer Variation | 1 | 2013 | 626 | 0.020 |
Why?
|
| Certification | 1 | 2012 | 66 | 0.020 |
Why?
|
| Perfusion Imaging | 1 | 2012 | 52 | 0.020 |
Why?
|
| Data Interpretation, Statistical | 1 | 2013 | 312 | 0.020 |
Why?
|
| Hospitals, Rural | 1 | 2010 | 8 | 0.020 |
Why?
|
| Hospitals, Community | 1 | 2010 | 35 | 0.020 |
Why?
|
| Critical Care | 1 | 2014 | 447 | 0.020 |
Why?
|
| Quality of Health Care | 1 | 2013 | 404 | 0.020 |
Why?
|
| Patient Safety | 1 | 2012 | 223 | 0.020 |
Why?
|
| Models, Neurological | 1 | 2013 | 434 | 0.020 |
Why?
|
| Young Adult | 2 | 2012 | 7025 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2011 | 886 | 0.020 |
Why?
|
| Evidence-Based Medicine | 1 | 2012 | 458 | 0.020 |
Why?
|
| Health Services Accessibility | 1 | 2013 | 491 | 0.020 |
Why?
|
| Genetic Variation | 1 | 2016 | 1423 | 0.020 |
Why?
|
| Data Collection | 1 | 2010 | 381 | 0.020 |
Why?
|
| Infusions, Intra-Arterial | 1 | 2009 | 41 | 0.020 |
Why?
|
| Heart Diseases | 1 | 2011 | 314 | 0.020 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2010 | 180 | 0.020 |
Why?
|
| Magnetic Resonance Angiography | 1 | 2011 | 277 | 0.020 |
Why?
|
| Carotid Artery, External | 1 | 2008 | 9 | 0.020 |
Why?
|
| Double-Blind Method | 1 | 2012 | 1791 | 0.020 |
Why?
|
| Databases, Factual | 1 | 2013 | 1010 | 0.020 |
Why?
|
| Drug Therapy, Combination | 1 | 2010 | 813 | 0.020 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2015 | 1469 | 0.020 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2012 | 935 | 0.020 |
Why?
|
| Clinical Competence | 1 | 2013 | 854 | 0.020 |
Why?
|
| Algorithms | 1 | 2016 | 2014 | 0.020 |
Why?
|
| Academic Medical Centers | 1 | 2010 | 422 | 0.020 |
Why?
|
| Disease Progression | 1 | 2011 | 1568 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2010 | 1546 | 0.020 |
Why?
|
| Retreatment | 1 | 2007 | 106 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 2010 | 1773 | 0.020 |
Why?
|
| Equipment Failure | 1 | 2007 | 128 | 0.020 |
Why?
|
| Biomarkers, Tumor | 1 | 2014 | 1665 | 0.010 |
Why?
|
| Hospitalization | 1 | 2011 | 943 | 0.010 |
Why?
|
| Blood Vessel Prosthesis Implantation | 1 | 2008 | 239 | 0.010 |
Why?
|
| Blood Pressure | 1 | 2009 | 929 | 0.010 |
Why?
|
| Synaptosomes | 1 | 2003 | 14 | 0.010 |
Why?
|
| Quantitative Structure-Activity Relationship | 1 | 2003 | 9 | 0.010 |
Why?
|
| Serotonin Plasma Membrane Transport Proteins | 1 | 2003 | 48 | 0.010 |
Why?
|
| Fluoxetine | 1 | 2003 | 42 | 0.010 |
Why?
|
| HeLa Cells | 1 | 2003 | 521 | 0.010 |
Why?
|
| Drosophila Proteins | 1 | 2003 | 523 | 0.010 |
Why?
|
| Rats | 1 | 2003 | 4154 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2008 | 3651 | 0.010 |
Why?
|
| Brain | 1 | 2003 | 2482 | 0.010 |
Why?
|